{"id":"NCT02164578","sponsor":"GWT-TUD GmbH","briefTitle":"Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk","officialTitle":"Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Type-2 Diabetic Patients With Very High Cardiovascular Risk and Subclinical Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2018-12-12","completion":"2020-04-30","firstPosted":"2014-06-16","resultsPosted":"2023-11-07","lastUpdate":"2023-11-07"},"enrollment":179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetic Patients"],"interventions":[{"type":"DRUG","name":"Rivaroxaban","otherNames":[]},{"type":"DRUG","name":"Aspirin","otherNames":[]}],"arms":[{"label":"Rivaroxaban","type":"EXPERIMENTAL"},{"label":"Aspirin","type":"ACTIVE_COMPARATOR"}],"summary":"Study to investigate microvascular and antiinflammatory effects of Rivaroxaban compared to low dose aspirin in type 2 diabetic patients.\n\nEspecially patients with cardiovascular disease and subclinical inflammation are in the focus of interest.","primaryOutcome":{"measure":"Change in Post-ischemic Forearm Blood Flow","timeFrame":"Baseline and week 20","effectByArm":[{"arm":"Rivaroxaban","deltaMin":3.6,"sd":4.69},{"arm":"Aspirin","deltaMin":1,"sd":5.27}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":5,"countries":["Germany"]},"refs":{"pmids":["34495376"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":89},"commonTop":[]}}